Abstract 301P
Background
During malignant transformation, the composition and expression of cell surface molecules are changing allowing recognition by the host immune system. Interleukin 17 (IL-17) is an inflammatory mediator involved in all phases of the inflammatory process and tumour development and progression. The aim of this study was to determine the IL-17 gene methylation level and IL-17 serum concentration in patients with different surrogate subtypes of early breast cancer (eBC) and healthy controls (HCs).
Methods
Peripheral blood samples were obtained from a consecutive series of 130 female patients treated at the University Hospital Centre (UHC) Zagreb, Croatia, and 30 female HCs. The level of methylation of four CpG dinucleotide loci (CPG1, CPG2, CPG3, CPG4) in the promoter region of the IL-17 gene was measured by pyrosequencing with prior bisulfite conversion, while serum IL-17 concentrations were determined by enzyme-linked immunosorbent assay (ELISA). Blood samples, clinical and histopathological data were collected with prior UHC Zagreb 02/21 AG Institutional Review Board approval.
Results
According to the Mann-Whitney test, the HCs methylation level of the promotor region of the IL-17 gene differed significantly from the BC patients (p = 0.0011), together with the methylation level of four individual CpG loci, also (p values; CPG1 0.0067; CPG2 0.0018; CPG3 CPG 0.0029; CPG4 0.0032, respectively). There was a statistically significant difference according to the Kruskal-Wallis test in CPG3 locus methylation among BC surrogate subtypes (p=0.010), whereas no difference in the methylation of the other three loci was observed. Preoperative IL-17 serum concentration was significantly higher in patients with HER-2 enriched and triple-negative eBC (Kruskal-Wallis test, p=0.022).
Conclusions
This study confirmed differences in epigenetic modification of IL-17 gene in women with eBC compared to HCs. Differences in the IL-17 gene methylation and IL-17 serum concentration in patients with different subtypes of BC were observed. Further research is planned to define the impact of IL-17 on eBC outcome in this cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research was funded by the grants from University of Zagreb for financial support to research groups 2019 and 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
233P - Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Presenter: Marianela Bringas Beranek
Session: Poster session 02
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02
236TiP - Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Presenter: Shingo Kitagawa
Session: Poster session 02
247P - KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
Presenter: Linxiaoxi Ma
Session: Poster session 02
248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Presenter: Francesca Ligorio
Session: Poster session 02
250P - The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer
Presenter: Luke Steventon
Session: Poster session 02
251P - Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Presenter: Jose Angel García-Sáenz
Session: Poster session 02